explore -WSS

explore

author：entertainment 2025-08-25 06:00:54 - browse：77552

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： White House drug czar issues call for 'recovery

hotspot

WSS

Medical school prerequisites are outdated

Experimental asthma app from Apple and Anthem shows promise

Gene therapy’s promise and the high cost of hope

Live blog: Hearing on CRISPR

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Carbon Health diabetes program, a test of data

leisure time

explore

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Carbon Health diabetes program, a test of data

United colonoscopy coverage change 'may cost lives,' doctors say

Humans aren't the only ones with an imagination. Rats have it too

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare’s new pay boost for primary care is angering specialists

Malaria cases in Florida and Texas: Here’s what you need to know

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Activists slam private health insurers over coverage restrictions

Ohio still needs to do more to protect the right to abortion

focus

Prime Medicine says its gene editing passes test in monkeys

NIH chief: government has fallen behind pharma on clinical trials

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Study suggests Covid rebound is far more common with Paxlovid than without

What is microchimerism and how does it affect maternal health?

Travis Kelce and the trap of celebrity vaccine endorsements

Wikipedia

focus

hotspot

Wikipedia